[go: up one dir, main page]

Latest News for: dll3

Edit

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 ...

Nasdaq Globe Newswire 02 Jul 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass ... 53 LR – Molecular Partners AG (SIX. MOLN; NASDAQ ... .
Edit

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 (Form 6-K) (Molecular Partners AG)

Public Technologies 02 Jul 2026
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712.
Edit

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712 (Molecular Partners AG)

Public Technologies 02 Jul 2026
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 ... DLL3 is a highly ... "MP0712 is a Radio-DARPin designed to attack tumors by specifically leveraging DLL3 biology.
Edit

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 (Form 6-K) (Molecular Partners AG)

Public Technologies 01 Jun 2026
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1 ... DLL3 is a highly relevant target for radiopharmaceutical therapy due ...
Edit

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing ...

Norfolk Daily News 31 May 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to ... .
Edit

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, ...

The Galveston Daily News 11 May 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2026-- ....
Edit

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

Nasdaq Globe Newswire 04 May 2026
MOLN; NASDAQ ... .
Edit

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences (Molecular Partners AG)

Public Technologies 04 May 2026
) PDF Version ... MOLN; NASDAQ ... Details of the events. ... May 6-7, Rockville, MD, USA. Title. Molecular characteristics of MP0712, a clinical stage ²¹²Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC). Session.
Edit

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, ...

The Milton Standard Journal 01 Apr 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 1, 2026-- ....
Edit

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and ...

The Daily Record - Dunn 30 Mar 2026
SOUTH SAN FRANCISCO, Calif., March 30, 2026 ....
Edit

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma

PR Newswire 30 Mar 2026
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor) ... DLL3 has been reported to be upregulated in multiple solid tumor types, including in SCLC, NETs, NSCLC, melanoma, among others.
  • 1

Article Search

tools
×
×
×
×